🇪🇺 IGOVOMAB in European Union

EMA authorised IGOVOMAB on 4 October 1996

Marketing authorisation

EMA — authorised 4 October 1996

  • Application: EMEA/H/C/000065
  • Marketing authorisation holder: CIS bio international
  • Local brand name: Indimacis 125
  • Indication: Positive diagnosis of relapsing ovarian adenocarcinoma when serum CA 125 is increased without positive results of ultrasound or computerised tomography scan.
  • Status: withdrawn

Read official source →

IGOVOMAB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in European Union

Frequently asked questions

Is IGOVOMAB approved in European Union?

Yes. EMA authorised it on 4 October 1996.

Who is the marketing authorisation holder for IGOVOMAB in European Union?

CIS bio international holds the EU marketing authorisation.